貴州百靈(002424.SZ)擬斥5100萬元投設內蒙古金靈佔股51%
格隆匯8月20日丨貴州百靈(002424.SZ)公佈,公司於2019年8月20日與白華、李彬宇、葛雲飛擬共同投資設立內蒙古金靈醫藥有限公司(“內蒙古金靈”或“投資標的”)(名稱以工商行政管理部門核准為準)簽訂了《出資協議》(“協議”)。內蒙古金靈註冊資本為1億元人民幣,公司擬使用自有資金出資5100萬元人民幣,佔51%股份,白華擬出資2500萬元人民幣,佔25%股份,李彬宇擬出資1400萬元人民幣,佔14%股份,葛雲飛擬出資1000萬元人民幣,佔10%股份。
內蒙古金靈醫藥有限公司(名稱以工商行政管理部門核准為準)經營範圍:麻醉藥品、精神藥品、醫療用毒性藥品、生物製品、中藥材、中藥飲片、中成藥、化學原料藥及其製劑、抗生素原料藥及其製劑、生化藥品、生物製品、疫苗、保健品;一類醫療器械、二類醫療器械(憑醫療器械備案經營許可證經營)、三類醫療器械;化粧品、電子設備、保健用品、辦公用品、勞保用品、日用化學品銷售;生物技術研發;倉儲。(以工商行政管理部門核准為準)
內蒙古自治區現階段的醫藥產業發展基礎相對薄弱,消費羣體的需求和政府相關政策的積極支持,對內蒙古區域未來的醫藥產業發展都有積極的促進作用。為了適應國家政策及行業發展趨勢,公司此次投資設立內蒙古金靈,將發揮公司營銷網絡資源優勢和成熟的經營模式,依託日益擴大的品牌效應和資本優勢,促進內蒙古金靈在內蒙古醫藥銷售行業的發展,進一步擴大公司經營規模,增強公司的市場競爭力和綜合盈利能力。
內蒙古金靈在內蒙古自治區發展醫藥產業的同時,也將作為公司在我國北部區域的醫藥基地,為企業進一步的發展奠定基礎。公司將緊緊抓住市場發展的時機,充分發揮自身營銷網絡資源優勢,從穩健原則和效益原則出發,向着把企業做大做強的目標邁進,提高公司抗風險能力,提高綜合盈利能力。
公司此次合作投資設立內蒙古金靈符合公司戰略發展目標的要求,公司將利用合作各方在資源上的優勢,形成資源互補、合作共贏的良好局面,同時能進一步完善和調整公司產業結構,符合公司發展戰略,有利於公司戰略佈局的推進,可為公司拓寬盈利渠道,提升公司綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.